RBI projects India's FY26 GDP growth at 7.4%, supported by a low 2.0% inflation forecast and a stable 5.25% repo rate, signaling a strong domestic consumption-led recovery.
Team Sahi
Market snapshot: On February 6, 2026, the Reserve Bank of India (RBI) underscored India's economic resilience by projecting a real GDP growth of 7.4% for the fiscal year 2025-26. This announcement, delivered by Governor Sanjay Malhotra, follows a series of proactive monetary policy adjustments throughout 2025. The projection reflects a 'Goldilocks' period for the Indian economy—characterized by solid domestic demand, benign inflation, and a supportive global trade environment following the recent India-US trade deal. Markets reacted with cautious optimism as the central bank maintained its 'Neutral' stance, choosing to pause its rate-cutting cycle to assess the impact of previous easing measures.
Summary: RBI projects India's FY26 GDP growth at 7.4%, supported by a low 2.0% inflation forecast and a stable 5.25% repo rate, signaling a strong domestic consumption-led recovery.
The RBI's projection of 7.4% is a clear signal that the domestic economy is decoupled from the sluggish growth seen in other major economies. By holding rates at 5.25%, the central bank is prioritizing the stabilization of bond yields and ensuring the transmission of previous rate cuts. Investors should look at this as a period of consolidation. The focus on liquidity management over further rate cuts suggests that the RBI is building a buffer against potential external shocks while allowing the government's ₹12.2 lakh crore capex push to filter through the infrastructure and real estate sectors.
As India positions itself to become the world's fourth-largest economy by the end of 2026, the RBI's balanced approach provides the necessary stability for long-term equity market performance.
High Performance Trading with SAHI.
Related
Recent
Fed's 2026 Outlook: Economic Resilience Meets Persistent Inflationary Pressures
Geopolitical Brinkmanship: Trump-Iran Tensions and the Indian Market Outlook
Zydus Lifesciences Disrupts Respiratory Care with India’s First Drug-Free Device 'Pepair' at ₹990
Infosys Pivots to 'AI-First' Era: New Framework Targets $300 Billion Market Opportunity
Zydus Lifesciences Disrupts Respiratory Care with India’s First Affordable Drug-Free Device ‘PepairTM’ at ₹990